Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Global Health

Novartis advances malaria therapy to Phase 3 study

by Michael McCoy
December 1, 2022 | A version of this story appeared in Volume 100, Issue 43

The structure of ganaplacide.

Novartis and the nonprofit Medicines for Malaria ­Venture are planning Phase 3 clinical trials in 2023 of a nonartemisinin treatment for people with malaria. The drug candidate combines the new molecule ganaplacide with a new formulation of lumefantrine. The ­current gold standard in malaria treatment is an artemether-lumefantrine combination, but malaria-causing parasites are becoming resistant to artemisinin derivatives like artemether, Novartis says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.